VT ablation in geriatric patients with structural heart disease: Should there still be an age limit?
complications after VT ablation in geriatric patients
mortality
recurrence
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
07
11
2020
revised:
30
12
2020
accepted:
03
01
2021
pubmed:
12
1
2021
medline:
10
8
2021
entrez:
11
1
2021
Statut:
ppublish
Résumé
This study sought to examine the feasibility and outcome of ablation of ventricular tachycardias (VTs) in a contemporary cohort of geriatric patients with structural heart disease (SHD). Geriatric patients are often underrepresented in large studies. As frailty is becoming an increasing problem, we need to examine the best course of action for this population. We investigated 68 SHD-patients ≥ 75 years old undergoing VT-ablation (men 88%, ischemic cardiomyopathy 77%, electrical storm 72%, mean left ventricular ejection fraction 31%) and divided the cohort into two groups: 75-79 years old (n = 51) and ≥80 years old (n = 17). The two groups showed similar results regarding noninducibility as ablation endpoint (p = .693), major procedure-related complications (p = .488), and VT-recurrence (p = .882) during the 39-month follow-up. At the end of the follow-up, 10 patients in the octogenarian group (59%) versus 16 patients of the other group (31%) died. Geriatric patients with SHD including octogenarians showed similar results regarding procedural endpoints, freedom of VT, and major procedure-associated complications after VT-ablation. When ablation is indicated, age alone should not be an inhibiting factor to treat these patients.
Sections du résumé
INTRODUCTION
This study sought to examine the feasibility and outcome of ablation of ventricular tachycardias (VTs) in a contemporary cohort of geriatric patients with structural heart disease (SHD).
BACKGROUND
Geriatric patients are often underrepresented in large studies. As frailty is becoming an increasing problem, we need to examine the best course of action for this population.
METHODS AND RESULTS
We investigated 68 SHD-patients ≥ 75 years old undergoing VT-ablation (men 88%, ischemic cardiomyopathy 77%, electrical storm 72%, mean left ventricular ejection fraction 31%) and divided the cohort into two groups: 75-79 years old (n = 51) and ≥80 years old (n = 17). The two groups showed similar results regarding noninducibility as ablation endpoint (p = .693), major procedure-related complications (p = .488), and VT-recurrence (p = .882) during the 39-month follow-up. At the end of the follow-up, 10 patients in the octogenarian group (59%) versus 16 patients of the other group (31%) died.
CONCLUSION
Geriatric patients with SHD including octogenarians showed similar results regarding procedural endpoints, freedom of VT, and major procedure-associated complications after VT-ablation. When ablation is indicated, age alone should not be an inhibiting factor to treat these patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
766-771Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Aronow WS. Treatment of ventricular arrhythmias in older adults. J Am Geriatr Soc. 1995;43:688-695.
Powell BD, Saxon LA, Boehmer JP, et al. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol. 2013;62:1674-1679.
Moss AJ, Greenberg H, Case RB, et al. Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group. Longterm clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760-3765.
Schron EB, Exner DV, Yao Q, et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002;105:589-594.
Sapp JL, Wells GA, Parkash R, et al. Ventricular tachycardia ablation versus antiarrhythmic-drug escalation. N Engl J Med. 2016;375:1499-1500.
Kheiri B, Barbarawi M, Zayed Y, et al. Antiarrhythmic drugs or catheter ablation in the management of ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators: a systematic review and meta-analysis of randomized controlled trials. Circ Arrhythm Electrophysiol. Epub. 2019;12(11):e007600.
Chen J, Hocini M, Larsen TB, et al. Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. Europace. 2015;17:314-317.
Darma A, Bertagnolli L, Dinov B, et al. Predictors of long-term mortality after catheter ablation of ventricular tachycardia in a contemporary cohort of patients with structural heart disease. Europace. 2020;22:1672-1679.
Vakil K, Garcia S, Tung R, et al. Ventricular tachycardia ablation in the elderly: an international ventricular tachycardia center collaborative group analysis. Circ Arrhythm Electrophysiol. 2017;10(12):e005332.
Inada K, Roberts-Thomson KC, Seiler J, et al. Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease. Heart Rhythm. 2010;7(6):740-744.
Frontera A, Panniker S, Breitenstein A, et al. Safety and mid-term outcome of catheter ablation of ventricular tachycardia in octogenarians. Europace. 2017;19(8):1369-1377.
Barra S, Begley D, Heck P, Turner I, Agarwal S. Ablation of ventricular tachycardia in the very elderly patient with cardiomyopathy: how old is too old? Can J Cardiol. 2015;31(6):717-722.
Dagres N, Piorkowski C, Kottkamp H, Kremastinos DT, Hindricks G. Contemporary Catheter ablation of arrhythmias in geriatric patients: patient characteristics, distribution of arrhythmias, and outcome. Europace. 2007;9(7):477-480.
Kautzner J, Peichl P, Sramko M, et al. Catheter ablation of atrial fibrillation in elderly population. J Geriatr Cardiol. 2017;14(9):563-568.